Clinical trials: MASLD, open to volunteers
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Measurement of spleen stiffness (SSM) has shown potential as a complementary tool to liver stiffness measurement (LSM) for the assessment of portal hypertension in patients with MASLD, particularly in the setting of compensated…
- Trial name
- S-MASH (NCT07440511)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis, Advanced Fibrosis, Sarcopenia
- Trial name
- EPSOMIP2 (NCT07312136)
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors
The Development of MASLD Among Survivors of Breast or Colorectal Cancer
A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly.
- Conditions
- Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- EVALUATE (NCT07280143)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Bern
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
To determine the effect of MTHF supplementation on serum folate and homocysteine level, metabolic, nutritional status, liver function, and PPARα and TNFα gene expression in patients with MASLD
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- MASLD (NCT07740109)
- Testing
- 5-methyltetrahydrofolate (5-MTHF)
- Where
- Iran
- Volunteers
- 44 people
- Sponsor
- Tabriz University of Medical Sciences
Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine…
- Trial name
- SEC-HOPE (NCT07683065)
- Where
- 7 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Steatotic Liver Disease, Fibrosis of Liver
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of…
- Trial name
- MASLD-DIAB (NCT07270822)
- Testing
- Collaborative care pathways group, Control group without intervention
- Where
- 10 sites in France
- Volunteers
- 1,714 people
- Sponsor
- Hospices Civils de Lyon
Metabolic-dysfunction Associated Liver Disease (MASLD)
Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
The purpose of this study is to understand if a behavioral lifestyle intervention called the Healthy Liver/Hígado Sano program can help Hispanic/Latino patients with metabolic dysfunction associated steatotic liver disease…
- Trial name
- NCT07199491
- Testing
- Healthy Liver/Hígado Sano program, Usual Care
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center, Houston
Metabolic Dysfunction-Associated Steatoic Liver Disease
A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic stress-related liver injury closely associated with insulin resistance, with a global prevalence of approximately 25%.
- Trial name
- NCT07878091
- Testing
- Kylo 0603 Capsule 8mg, Kylo 0603 Capsule 12mg, Kylo 0603 Capsule 16mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Metabolic Dysfunction-Associated Liver Disease
Pilot Study for Collecting Data on Liver Adipose Content in Adults by Ultrasound Attenuation and Scattering Imaging and MRI Proton-density
The aim of this single-center, prospective, pilot study is to acquire data on liver adipose content in a population of adult patients affected by MASLD (Metabolic Dysfunction-Associated Liver Disease).
- Trial name
- QAI_QSI_MRI (NCT07189650)
- Testing
- MRI
- Volunteers
- 30 people
- Sponsor
- Esaote S.p.A.
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing due to changes in economic conditions and lifestyle, and it is anticipated to become a significant liver disease burden in the…
- Trial name
- NCT06762223
- Testing
- Henagliflozin 10 mg daily, Metformin 1700 mg daily
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Xiqiao Zhou
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
EVOO and Metabolic Liver Health in MASLD
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and…
- Trial name
- EvoLiveR (NCT07412444)
- Testing
- Oil Supplementation - 3 tablespoons of oil, 9 Tablespoons of Oil
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
MASH, MASLD
Global Research Initiative for Patients Screening on MASH
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe…
- Conditions
- MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
- Trial name
- GRIPonMASH (NCT05651724)
- Where
- 13 sites in Belgium, Czechia and 8 more
- Volunteers
- 10,000 people
- Sponsor
- Julius Clinical
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is an increasingly recognized comorbidity in people living with human immunodeficiency virus (HIV).
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis
- Trial name
- NCT07861594
- Volunteers
- 250 people
- Sponsor
- Assiut University
NAFLD, Cardiac Disease
Cardiac Dysfunction in Patients with Fatty Liver Disease
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease.
- Conditions
- NAFLD, Cardiac Disease, Fatty Liver, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT06386094
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Early Motherhood
Temporal Eating Patterns and Metabolic Health
Obesity and its related health problem, like fatty liver disease and type 2 diabetes, are major health problems worldwide and can lead to serious illness and reduced quality of life.
- Trial name
- TIME-MET (NCT07630636)
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Maria Chondronikola
Menopause, Metabolic Dysfunction Associated Steatotic Liver Disease
COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide, currently affecting approximately 1-in-4 people globally.
- Trial name
- NCT06704516
- Testing
- Menopausal hormone therapy
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Oxford